메뉴 건너뛰기




Volumn , Issue , 2008, Pages 771-786

Use of erythropoietic-stimulating agents in hemodialysis patients

Author keywords

[No Author keywords available]

Indexed keywords


EID: 79960732673     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4197-9.50063-6     Document Type: Chapter
Times cited : (3)

References (16)
  • 1
    • 0023120533 scopus 로고
    • Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
    • Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. New Engl J Med 1987, 316:73-78.
    • (1987) New Engl J Med , vol.316 , pp. 73-78
    • Eschbach, J.W.1    Egrie, J.C.2    Downing, M.R.3    Browne, J.K.4    Adamson, J.W.5
  • 2
    • 0024790160 scopus 로고
    • Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter trial
    • Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter trial. Ann Intern Med 1989, 111:992-1000.
    • (1989) Ann Intern Med , vol.111 , pp. 992-1000
    • Eschbach, J.W.1    Abdulhadi, M.H.2    Browne, J.K.3
  • 3
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    • Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson R, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 1998, 339:584-590.
    • (1998) New Engl J Med , vol.339 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3    Egrie, J.C.4    Nissenson, R.5    Okamoto, D.M.6
  • 4
    • 33646345152 scopus 로고    scopus 로고
    • NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease
    • National Kidney Foundation NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006, 47(3):S1-146.
    • (2006) Am J Kidney Dis , vol.47 , Issue.3
    • National Kidney Foundation1
  • 5
    • 84882909419 scopus 로고    scopus 로고
    • National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for American Chronic Kidney Disease. 2007 Update on Hemoglobin Target
    • National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for American Chronic Kidney Disease. 2007 Update on Hemoglobin Target. Am J Kidney Dis, 2007, in press.
    • Am J Kidney Dis, 2007, in press
  • 6
    • 0034765367 scopus 로고    scopus 로고
    • Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%
    • Collins AJ, Li S, St.Peter W, Ebben J, Roberts T, Ma JZ, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001, 12:2465-2473.
    • (2001) J Am Soc Nephrol , vol.12 , pp. 2465-2473
    • Collins, A.J.1    Li, S.2    St.Peter, W.3    Ebben, J.4    Roberts, T.5    Ma, J.Z.6
  • 7
    • 0033052842 scopus 로고    scopus 로고
    • Hematocrit level and associated mortality in hemodialysis patients
    • Ma JZ, Ebben J, Xia H, Collins AJ Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999, 10:610-619.
    • (1999) J Am Soc Nephrol , vol.10 , pp. 610-619
    • Ma, J.Z.1    Ebben, J.2    Xia, H.3    Collins, A.J.4
  • 8
    • 0037075272 scopus 로고    scopus 로고
    • Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
    • Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
    • (2002) N Engl J Med , vol.346 , pp. 469-475
    • Casadevall, N.1    Nataf, J.2    Viron, B.3
  • 9
    • 9644283016 scopus 로고    scopus 로고
    • Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysi of randomized controlled trials
    • Strippoli GFM, Craig JC, Manno C, Schena FP Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysi of randomized controlled trials. J Am Soc Nephrol 2004, 15:3154-3165.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 3154-3165
    • Strippoli, G.F.M.1    Craig, J.C.2    Manno, C.3    Schena, F.P.4
  • 10
    • 29244456140 scopus 로고    scopus 로고
    • Evidence-based systematic literature review of the literature of hemoglobin/hematocrit and all-cause mortality in dialysis patients
    • Volkova N, Arab L Evidence-based systematic literature review of the literature of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006, 47:24-26.
    • (2006) Am J Kidney Dis , vol.47 , pp. 24-26
    • Volkova, N.1    Arab, L.2
  • 11
    • 84882832206 scopus 로고    scopus 로고
    • These two articles are the first reported results in dialysis patients of the use of recombinant human erythropoietin. The results are important in terms of how this transformed anemia management in patients on dialysis and subsequently with anemia due to other conditions.
  • 12
    • 84882832968 scopus 로고    scopus 로고
    • This article describes what remains as the largest clinical trial prospectively studying the clinical outcomes resulting from low versus normal hematocrit/hemoglobin levels in dialysis patients. There was a trend toward a higher combined mortality and first nonfatal myocardial infarction in the higher hematocrit group, leading to the early termination of the study.
  • 13
    • 84882883915 scopus 로고    scopus 로고
    • These two articles are the most recent revisions to the NKF-K/DOQI clinical practice guidelines and recommendations for adults and children with anemia and CKD.
  • 14
    • 84882851852 scopus 로고    scopus 로고
    • This article reviews two observational studies that examined the association between hematocrit and outcomes in hemodialysis patients using Medicare/HCFA databases that support the clinical practice of maintaining hemoglobin levels in the range of 11 to 12 g/dL.
  • 15
    • 84882856804 scopus 로고    scopus 로고
    • This is the original description of pure red cell aplasia due to antierythropoietin antibodies.
  • 16
    • 84882914245 scopus 로고    scopus 로고
    • This article reviews the available studies concerning the outcomes associated with hemoglobin levels in hemodialysis patients.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.